**Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies**

Yu-Cheng Su1,2, Talal S Al-Qaisi1,2, Hsin-Yi Tung2,3, Tian-Lu Cheng4, Kuo-Hsiang Chuang5, Bing-Mae Chen2 and Steve R Roffler2,*

1Program in Molecular Medicine; National Yang-Ming University and Academia Sinica; Taipei, Taiwan; 2Institute of Biomedical Sciences; Academia Sinica; Taipei, Taiwan; 3Taiwan International Graduate Program; National Yang-Ming University; Taipei, Taiwan; 4Faculty of Biomedical Science and Environmental Biology; MedicoGenomic Research Center; Kaohsiung Medical University; Kaohsiung, Taiwan; 5Graduate Institute of Pharmacognosy; Taipei Medical University; Taipei, Taiwan

**Keywords:** germinal center reaction, somatic hypermutation, class switch recombination, AID, activation-induced cytidine deaminase, affinity maturation, polyethylene glycol, PEG, temperature-dependent binding, hybridoma, temperature-selective antibody, anti-PEG

**Abbreviations:** AID, activation-induced cytidine deaminase; CDR, complementarity-determining region; CSR, class switch recombination; eGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorting; FR1, framework one of the variable region gene segment; HA, hemagglutinin; HEL, hen egg white lysozyme; mAbs, monoclonal antibodies; MFI, mean fluorescence intensity; PEG, polyethylene glycol; pre-B cells, precursor B cells; pro-B cells, progenitor B cells; pCMV-AID-loxP, lentiviral vector for stoppable expression of AID; pTetOn-AID, lentiviral vector for tetracycline-inducible expression of AID; SHM, somatic hypermutation; V-D-J, heavy chain variable, diverse and joining gene segments; V\textsubscript{L}, light chain variable region

Introduction

Monoclonal antibodies (mAbs) play important roles in medicine and biotechnology due to their high specificity and affinity. Elegant mutagenesis and engineering strategies have been developed to alter the antigen-binding properties of antibodies, including complementarity determining region (CDR) mutagenesis,1,2 error-prone PCR3 and DNA shuffling.4 Powerful yeast and mammalian antibody display systems have been developed in parallel to improve antibody properties.5,6 These approaches, however, can be technically challenging, time-consuming and expensive, largely restricting these technologies to laboratories and companies with specialized facilities and expertise.

In the mammalian immune system, progenitor B cells (pro-B cells) and precursor B cells (pre-B cells) in the bone marrow undergo V-D-J gene segment rearrangement at the heavy chain locus and then V\textsubscript{L} gene rearrangement at the light chain loci to generate the primary B cell receptor repertoire.7 Contact of B cells with cognate antigen in germinal centers along with both membrane-bound and secreted signals provided by T follicular helper cells leads to somatic hypermutation (SHM) by induction of activation-induced cytidine deaminase (AID) dependent deamination of cytidine, followed by error-prone DNA repair...
that introduces point mutations in the V regions of immunoglobulin genes in centroblast B cells.\(^8,9\) Rapidly dividing centroblasts in the dark zone of the germinal center migrate to the light zone to become centrocytes, express surface immunoglobulin and compete for limiting quantities of antigen on follicular dendritic cells (Fig. 1A). Centrocytes that display antibodies with higher affinity preferentially interact with antigen and survive to migrate back into the dark zone for further proliferation and SHM. Multiple rounds of SHM and selection coupled with AID-mediated heavy-chain class switch recombination (CSR) results in B cells that secrete high affinity IgG, IgA and IgE antibodies.\(^10\)

Previous studies have elegantly demonstrated that ectopic expression of AID in hybridoma cells can induce SHM and CSR of antibodies.\(^11,12\) Here, we sought to extend these observations to mimic the germinal center reaction directly in antibody-secreting hybridoma cells (Fig. 1B). We therefore expressed the mouse AID gene in hybridoma cells to induce SHM and CSR. After periods of cell expansion and SHM, we mimicked centrocyte competition for antigen by incubating the hybridoma population with fluorescence-labeled antigen and selected desirable variants by high-throughput fluorescence-activated cell sorting (FACS) of hybridoma cells (Fig. 1B).

We investigated this strategy to isolate antibodies that bind to a conformation of PEG that is preferentially formed at 4°C. PEG is a polymer with repeating subunits of ethylene glycol [HO-(CH\(_2\)-CH\(_2\)-O)n-H]. Covalent attachment of PEG (PEGylation) is widely used in the pharmaceutical and biotechnology industries to improve the pharmacokinetic properties of small molecules, nucleotides, peptides, proteins and nanoparticles by increasing drug solubility, reducing renal clearance, enhancing serum half-life, diminishing engulfment by phagocytes and decreasing proteolytic degradation.\(^13\) Previous studies suggest that PEG conformation may be temperature-dependent, preferentially existing in a gauche structure at lower temperatures, but possessing a trans conformation at higher temperatures.\(^14,15\) However, direct evidence for distinct PEG conformations at different temperatures remains elusive.

Here, we show that mAbs that preferentially bind to PEG at 4°C could be isolated in an anti-PEG hybridoma. We also demonstrate rapid CSR of IgM to IgG antibodies in hybridoma cells. This methodology may represent a general strategy to enhance antibody properties with “on demand” SHM and CSR without the need for antibody engineering and recombinant protein expression.

**Results**

Surface antibodies can be used to identify antigen-specific hybridoma cells

Naive B cells express on their surface multiple copies of antibodies with the identical amino acid sequence and antigen specificity. Upon antigen stimulation and differentiation into plasma cells, membrane antibodies are converted to secreted antibodies by RNA splicing and processing of the primary RNA transcript to remove the hydrophobic transmembrane anchor. However, RNA splicing may be incomplete in hybridoma cells, which would greatly facilitate selection of antibodies with altered binding properties. We therefore used immunofluorescence staining to detect immunoglobulin on the plasma membrane of live hybridoma cells. All tested antibody-secreting hybridoma cells, including those that secrete IgG\(_1\), IgG\(_2\), IgG\(_3\), IgG\(_4\), IgG\(_5\), and IgM antibodies, displayed moderate to high levels of membrane immunoglobulin on their surface compared with FO myeloma cells, which do not express immunoglobulin (Fig. 2A). The functional activity of membrane immunoglobulin on hybridoma cells was examined by labeling 3.3 (anti-PEG) and 7G8 (anti-β-glucuronidase) hybridoma cells with biotinylated polyethylene glycol (PEG) or β-glucuronidase, followed by Alexa Fluor 647-conjugated streptavidin. 3.3 hybridoma cells specifically bound PEG but not β-glucuronidase, whereas 7G8 hybridoma cells bound β-glucuronidase but not PEG (Fig. 2B), showing that membrane immunoglobulin displayed the expected antigen-binding specificities. To investigate whether high-throughput FACS of hybridoma cells based on antigen-binding by surface immunoglobulin is feasible, a mixture of 7G8 (anti-β-glucuronidase) and 3.3 (anti-PEG) hybridoma cells (99:1 ratio) was stained with biotinylated PEG and then incubated with Alexa Fluor 647-conjugated streptavidin. Two distinct populations of cells could be clearly differentiated, corresponding to the ratio of the input 7G8 and 3.3 cells (Fig. 2C, left panel). The hybridoma cells that bound PEG were collected and cultured for 5 d. Analysis of the expanded hybridoma cells
showed that they could bind PEG (Fig. 2C, right panel), indicating efficient selection of 3.3 anti-PEG hybridoma cells. We conclude that antibody-secreting hybridoma cells display sufficient functional immunoglobulin on their surface to allow identification and isolation of antigen-specific hybridoma cells.

**Controllable induction of SHM**

We constructed constitutive and inducible vectors to allow controllable expression of activation-induced cytidine deaminase (AID) in hybridoma cells. These vectors were designed to facilitate termination of AID expression once antibody variants with desirable features are identified. A loxP-flanked constitutive expression cassette (pCMV-AID-loxP) (Fig. 3A) was used to stably transduce 3.3 anti-PEG hybridoma cells by lentiviral infection, making 3.3/loxP-AID cells. AID was expressed in 3.3/loxP-AID cells as indicated by the fluorescence of the eGFP reporter protein (Fig. 3B, left panel). To test whether the expression of AID could be stopped “on demand,” the pLM-mCherry-P2A-Cre plasmid was transferred into 3.3/loxP-AID cells by DNA electroporation. About 23% of the cells expressed Cre recombinase as visualized by mCherry expression, corresponding to the cell population that displayed reduced eGFP expression (Fig. 3B, middle panel), indicating deletion of the AID gene cassette. The eGFP-negative cells could be easily isolated by FACS (Fig. 3B, right panel). mCherry was transiently expressed and was therefore no longer detectable in these cells. To confirm CRE-dependent deletion of the AID gene, total cell lysates prepared from 3.3 cells, 3.3/loxP-AID cells or sorted Cre-infected 3.3/loxP-AID cells were separated by SDS-PAGE and AID was detected via a C-terminal hemagglutinin (HA) epitope tag sequence on western blots using an anti-HA antibody. AID protein was detected in 3.3/loxP-AID cells but was absent in Cre-treated 3.3/loxP-AID cells (Fig. 3C), demonstrating that AID could be stably expressed and conditionally silenced by Cre recombinase mediated gene deletion in hybridoma cells.

A tetracycline-inducible AID expression cassette (pTetOn-AID) was also constructed as an alternative for controllable induction of AID expression. Doxycycline can bind to rtTA-V14 to form an active transactivator to initiate DNA transcription driven by the pTRE promoter in a feed forward loop (Fig. 3D). Stably infected 3T3/TetOn-AID cells incubated with graded concentrations of doxycycline for two days displayed dose-dependent induction of the eGFP reporter, corresponding to inducible expression of AID (Fig. 3E). To examine if AID was functionally competent to induce SHM, 3T3 or 3T3/TetOn-AID cells were stably transfected with a DsRed2 gene, in which tyrosine 173 was mutated to an amber stop codon in the context of a RGYW/WRCY AID consensus hot spot motif (Fig. 3F). DsRed2 fluorescence was only detected in the 3T3/TetOn-AID transfectants after initiation of SHM by addition of doxycycline (Fig. 3G). We conclude that these AID expression cassettes allow controllable expression of AID for induction of SHM.

**Mimicking the germinal center reaction in vitro**

We expressed AID in 3.3 anti-PEG hybridoma cells to isolate anti-PEG antibodies that bind to PEG at low temperatures with high affinity. This was accomplished by expanding 3.3/loxP-AID cells to allow SHM, staining the cells with fluorescence-labeled antigen (PEG) on ice, selecting hybridoma cells that bind the most PEG by FACS and expanding the selected cells for two weeks to allow continued SHM. Initial selection was performed with long-chain multivalent PEG molecules but the PEG length and valency was progressively decreased in subsequent rounds of cell sorting. After five sequential rounds of cell expansion and sorting, hybridoma cell samples collected after each round of sorting were stained with Alexa Fluor 647-conjugated streptavidin. Hybridoma cells that bound biotin-PEG (left panel) were collected with a fluorescence-activated cell sorter, cultured for 5 d and then stained with biotin-PEG and Alexa Fluor 647-streptavidin (right panel).

![Figure 2. Analysis of membrane immunoglobulin on hybridoma cells.](image)

- **A** Membrane-bound immunoglobulin on hybridoma and FO myeloma cells was detected by flow cytometry after staining the cells with goat anti-mouse Ig and rabbit anti-goat FITC.
- **B** Functional antigen-binding of membrane immunoglobulin on 3.3 anti-PEG and anti-β-glucuronidase 7G8 hybridoma cells was detected on a flow cytometer with biotinylated PEG or β-glucuronidase antibodies followed by Alexa Fluor 647-conjugated streptavidin.
- **C** 7G8 anti-β-glucuronidase and 3.3 anti-PEG hybridoma cells mixed at a ratio of 99:1 were stained with 0.5 nM biotin-PEG and Alexa Fluor 647-conjugated streptavidin. Hybridoma cells that bound biotin-PEG were collected with fluorescence-activated sorts, cultured for 5 d and then stained with biotin-PEG and Alexa Fluor 647-streptavidin.
observed for three hybridoma clones (1E3, 1E10, and 2B5) isolated by single-cell sorting of the 3.3/loxP hybridoma cells after the fifth round of selection (Fig. 4B). Sequence analysis of the immunoglobulin variable region genes from the 3.3 subclones revealed that all three antibody variants exhibited a common A23V mutation in framework 1 (FR1) of the V_H chain and a common N53K mutation in CDR2 of the V_L chain (Fig. 4C). In addition, both 1E10 and 2B5 antibodies possessed an A55P mutation in CDR2 of the VL chain while 1E10 exhibited an additional mutation, S92T, in CDR3 of the VL chain.

Anti-PEG antibody variants selectively bind PEG at low temperatures

We evaluated the temperature-dependent binding of two of the 3.3 antibody variants (1E3 and 2B5) to PEG (10,000 Da) coated in microtiter plates. The 2B5 variant bound PEG with greater apparent affinity than the parental 3.3 antibody whereas 1E3 bound about as well as 3.3 at 4°C, but both variant antibodies displayed progressively reduced binding to PEG at 25°C or 37°C (Fig. 5A). Analysis of antibody binding to PEG by surface plasmon resonance showed that 2B5 and 1E3 displayed similar affinity as the parental 3.3 antibody at 4°C, but that the affinity of 1E3 and 2B5 for PEG at 25°C was decreased by 85 and 185-fold, respectively, compared with their affinities at 4°C (Table 1). The affinities of 1E3 and 2B5 could not be determined at 37°C due to poor binding to PEG. Similar temperature-selective recognition by 1E3 and 2B5 was observed for other lengths of PEG coated in microtiter plates (Fig. S1). We also observed that 1E3 and 2B5 displayed enhanced binding of long-chain PEG, but reduced binding to short PEG molecules (i.e., 750 Da PEG) compared with the parental 3.3 antibody. 1E3 and 2B5 antibodies were not inherently unstable at elevated temperatures because even after incubation at 37°C for 5 d, they retained full binding.
activity (Fig. 5B). Furthermore, the melting temperatures of 1E3 and 2B5 antibodies (73.6°C and 74.2°C, respectively), as determined by differential scanning calorimetry, were actually higher than the parental 3.3 antibody (70.8°C), indicating that 1E8 and 2B5 antibodies were thermostable (Fig. 5C). These results indicate that the AID induced mutations in the immunoglobulin V region genes of 1E3 and 2B5 antibodies conferred the ability to preferentially bind to PEG at 4°C.

**Roles of the CDR mutations in temperature-dependent PEG binding**

To determine which mutations are responsible for the temperature-dependent binding of the antibody variant 2B5, we individually reverted the conserved amino acid mutations in 2B5 (VH V23A and VL K53N) back to the corresponding amino acids in the parental 3.3 antibody (Fig. 6A). Reversion of VH V23 to alanine did not eliminate the temperature dependent binding of 2B5ΔV to PEG (Fig. 6B). By contrast, replacement of VL K53 with asparagine abolished the temperature-selective binding of 2B5ΔK to PEG as observed by similar binding of 2B5ΔK to PEG at 4°C, 25°C and 37°C (Fig. 6B). We conclude that the VL K53 mutation is responsible for the temperature-dependent binding of 2B5 to PEG.

**2B5 binds to a PEG structure that can be mimicked by crown ether**

Several studies have reported that PEG can coordinate lysine residues to form crown ether-like structures on the surface of proteins crystals. We therefore hypothesized that 2B5 may recognize a PEG conformation that can be mimicked by crown ether (Fig. 7A). Indeed, 18-crown-6 completely blocked binding of a fixed amount of 2B5 to immobilized methoxy-PEG₅₅-NH₂ at 4°C in a dose-dependent fashion (Fig. 7B, upper panel). By contrast, 18-crown-6 was a relatively poor competitor for binding of the parental 3.3 antibody to PEG (Fig. 7B, upper panel). 18-crown-6 did not affect the binding of an isotype-matched anti-β-glucuronidase control antibody (7G8) to immobilized β-glucuronidase (Fig. 7B, lower panel), demonstrating specificity of the competition reaction. We further reasoned that if 18-crown-6 mimics a PEG structure that forms at 4°C, then 2B5 should bind to the structurally-defined 18-crown-6 at all temperatures. We therefore examined by surface plasmon resonance the binding of 2B5 to 2-aminomethyl-18-crown-6 immobilized on a CM5 chip at three different temperatures (4°C, 25°C and 37°C). 2B5 bound to immobilized 18-crown-6 at all temperatures tested, whereas 3.3 and control 7G8 antibodies showed relative low binding or non-binding to immobilized 18-crown-6, respectively (Fig. S2). Likewise, we detected 2B5 binding to 2-aminomethyl-18-crown-6 coated in 96-well ELISA plates at 4°C, 25°C and 37°C (Fig. 7C). We conclude that 2B5 binds to a PEG structure that preferentially forms at 4°C and that can be mimicked by 18-crown-6.

**Thermal affinity purification of PEGylated nanoparticles by 2B5 antibody**

We further explored whether 2B5 anti-PEG antibody could be employed for mild affinity purification of PEGylated compounds. PEG-Qdots in cold PBS (4°C) were loaded onto a
In situ class switch recombination of antibodies

CSR of antibody heavy chain genes from IgM to other antibody classes in the germinal center also depends on AID activity.\textsuperscript{23} We therefore examined if expression of AID could facilitate isolation of class-switched antibodies. The pCMV-AID-\textit{loxP} vector was used to stably transduce AGP4 and 3D8 hybridoma cells by lentiviral infection. AGP4 hybridoma cells secrete a monoclonal IgM that binds to PEG whereas 3D8 hybridoma cells secrete a monoclonal IgM that binds to an antigen expressed on the surface of mouse B16F10 melanoma cells.\textsuperscript{23,24} The hybridoma cells were cultured for four weeks and then live hybridoma cells were stained with fluorescence-labeled PEG (AGP4 hybridoma cells) and PE-conjugated goat anti-mouse IgG (AGP4 and 3D8 hybridoma cells) and individual positive cells were sorted by FACS into individual wells of a 96-well culture plate. The heavy chain class of antibodies in the culture medium of AGP4/\textit{loxP}-AID and 3D8/\textit{loxP}-AID clones was examined by ELISA. As expected, only IgM antibodies were detected in the culture medium from the parental AGP4 and 3D8 hybridoma cells (Fig. 9A and B). By contrast, all selected AGP4/\textit{loxP}-AID and 3D8/\textit{loxP}-AID hybridoma clones secreted IgG antibodies, confirming class switch from IgM to IgG. Further analysis of the isotype of AGP4 and 3D8 class-switched antibodies revealed that they were all IgG\textsubscript{\textgamma}. The class-switched antibodies retained antigen-binding activity as determined by ELISA (Fig. 9C and D). However, sequencing of the heavy chain variable region genes of the class-switched 3D8 antibodies revealed amino acid changes in AID consensus hot spots (Table S1), indicating that SHM also occurred during CSR. We conclude that mimicking the germinal center reaction can facilitate rapid conversion of IgM to IgG antibodies with concurrent SHM.

Discussion

Here, we show that the germinal center reaction can be mimicked in hybridoma cells to facilitate isolation of mAbs with altered binding properties and class-switched heavy chains. This simple procedure entails lentiviral infection of an AID gene into hybridoma cells to induce SHM and CSR followed by rounds of expansion and selection of hybridoma cells that display surface immunoglobulin with the desired binding properties and antibody isotypes. Because each hybridoma cell expresses multiple copies of a single antibody variant on its surface, selection can be rapidly achieved by FACS of a large population of antigen-stained hybridoma cells. We demonstrated the utility of this approach by generating for the first time a mAb that preferentially binds to a conformation of PEG that forms at reduced temperature (4°C) and could be mimicked by crown ether. The variant anti-PEG antibodies were more thermostable than the parental antibody and could be easily produced by conventional hybridoma cell culture. We further demonstrated simple and rapid class switch of monoclonal IgM antibodies to IgG directly in hybridoma cells with the caveat that simultaneous SHM may alter antibody binding properties. Taken together, our study indicates that this approach may help generate improved or class-switched antibodies without the need for antibody library construction, antibody engineering or recombinant antibody production.

AID is both necessary and sufficient to induce SHM in B cells via a process that involves deamination of cytidine followed by error-prone DNA repair to introduce point mutations in the V regions of immunoglobulin genes.\textsuperscript{9} The power of ectopic AID expression has been recognized in elegant studies demonstrating

![Figure 5. Temperature-dependent binding and stability of anti-PEG antibody variants.](image-url)
CSR in hybridoma cells and affinity maturation of antibody libraries in HEK293 cells engineered to express AID. Nevertheless, the HEK293 platform requires substantial technical expertise because it entails construction of antibody gene libraries, transfection of antibody libraries into HEK293 cells, selection of the desired antibody variants and mammalian cell production of the final recombinant antibodies. By contrast, we found that antibody variants could be selected by expressing AID in hybridoma cells and directly interrogating immunoglobulins present on the surface of hybridoma cells, presumably due to incomplete splicing of the immunoglobulin heavy chain gene RNA transcript from the transmembrane to the secreted form. We stained hybridoma cells with fluorescence-labeled antigen to rapidly collect desirable antibody variants.

We previously generated several mAbs that bind the repeating ethylene oxide subunits present in PEG. These antibodies have found widespread use in the biotechnology and pharmaceutical industries for the laboratory and clinical analysis of PEGylated therapeutic agents. Previous reports have suggested that PEG tertiary conformation in aqueous solutions may depend on temperature. We reasoned that antibody variants that preferentially bind the “low temperature” conformation of PEG could be selected by mimicking the germinal center reaction in 3.3 anti-PEG hybridoma cells and selecting variants with fluorescence-labeled PEG at low temperature. Indeed, we isolated antibodies that bound more strongly to PEG at 4°C compared with 37°C. Poor binding at 37°C was not due to antibody instability at elevated temperatures because the new antibodies were at least as stable as the parental 3.3 antibody as determined by differential scanning calorimetry. Rather, the new antibodies were found to bind to a PEG conformation that can be competed by a cyclic ethylene oxide structure (18-crown-6).

Mutagenesis studies revealed that a lysine substitution in the light chain variable region of 3.3 conferred the ability to bind to the crown ether-like PEG structure. Our results are consistent with a model in which the parental 3.3 antibody can bind to a form of PEG that is present at all temperatures, whereas 1E3 and 2B5 can selectively bind to a cyclic ethylene oxide structure that is present in PEG molecules at low temperature only. The new lysine residue in 1E3 and 2B5 variant antibodies appears to interfere with the normal binding mode of 3.3 to PEG, resulting in poor binding of the variant antibodies to PEG at 37°C. We speculate that the terminal ammonium group of the new lysine residue in the binding pocket of 1E3 and 2B5 antibodies may coordinate oxygen atoms in PEG chains that form cyclic ethylene oxide structures at lower temperatures (4°C), thereby compensating for decreased binding via the “standard 3.3” binding mode. The cyclic ethylene oxide structures in PEG molecules appear to form

| Temperature | 4°C | 25°C | 37°C |
|-------------|-----|------|------|
| Antibody    | $k_{on}$ ($M^{-1}s^{-1}$) | $k_{off}$ ($s^{-1}$) | $K_d$ ($M$) | $k_{on}$ ($M^{-1}s^{-1}$) | $k_{off}$ ($s^{-1}$) | $K_d$ ($M$) | $k_{on}$ ($M^{-1}s^{-1}$) | $k_{off}$ ($s^{-1}$) | $K_d$ ($M$) |
| 3.3         | (0.9 ± 0.12)  $\times 10^3$ | (5.2 ± 0.50)  $\times 10^7$ | (9.6 ± 1.67)  $\times 10^3$ | (1.2 ± 0.70)  $\times 10^7$ | (1.3 ± 0.17)  $\times 10^3$ | (1.5 ± 0.03)  $\times 10^4$ | (3.1 ± 0.22)  $\times 10^4$ | (2 ± 0.11)  $\times 10^3$ |
| 1E3         | (2.1 ± 0.13)  $\times 10^3$ | (3.4 ± 0.04)  $\times 10^4$ | (2.8 ± 0.22)  $\times 10^3$ | (2.9 ± 0.16)  $\times 10^3$ | NM*          | NM            | NM            | NM            |
| 2B5         | (3.6 ± 0.02)  $\times 10^3$ | (4.7 ± 0.06)  $\times 10^3$ | (1.6 ± 0.02)  $\times 10^3$ | (14.2 ± 0.64)  $\times 10^3$ | (8.7 ± 0.47)  $\times 10^3$ | NM            | NM            | NM            |

The binding of 3.3, 1E3, and 2B5 Fab fragments to PEG immobilized on a CM5 chip was determined in a Biacore T-200. Results represent mean values of triplicate determinations ± SD. NM, not meaningful, no reading at all concentrations.
Our approach may also be useful for temperature-dependent elution as we demonstrated for a PEGylated gentle bio-separation of PEGylated compounds based on temperature controllable gated nanodevices and for cations such as temperature tunable capture of nanoparticles, temperature-dependent fashion may be useful for novel applications. At low temperature, 1E3 and 2B5 selectively bind PEG structures at 4°C. Thus, 3.3 may bind to a form of PEG ethylene oxide structure may represent only a fraction of total capacities such as temperature tunable capture of nanoparticles, temperature-dependent fashion may be useful for novel applications.

Antibodies able to discriminate PEG conformation in a temperature-dependent fashion may be useful for novel applications such as temperature tunable capture of nanoparticles, creation of temperature controllable gated nanodevices and for gentle bio-separation of PEGylated compounds based on temperature-dependent elution as we demonstrated for a PEGylated nanoparticle. Our approach may also be useful for developing selective antibodies against new stimulus-responsive peptides and polymers currently under development.

Although the affinity of 2B5 appeared to be increased compared with the parental 3.3 antibody (Fig. 5A), the major effect was attainment of the new property of temperature-selective binding to PEG. In the present study, we used progressively less branched and shorter PEG molecules to select hybridoma cells. By contrast, centrocytes in germinal centers are selected on limiting amounts of antigen, which may drive selection of higher affinity antibodies. Conditions for rapid affinity maturation are currently under investigation, but preliminary results using progressively decreasing doses of antigen for selection of hybridoma cells during FACS indicates that antibody affinity can indeed be increased by this procedure.

Besides SHM, germinal center B cells also undergo CSR, in which the C4 heavy chain constant region gene is replaced with downstream Cγ, Cα or Cε genes (i.e., switch from IgM to IgG, IgA or IgE). The combination of AID expression and FACS facilitated rapid switching and identification of AGP4 and 3D8 hybridoma cells that switched from secreting IgM antibodies to IgG antibodies. In our study, we sorted IgG-positive hybridoma cells so it was not surprising that we did not isolate IgE or IgA antibodies. Interestingly, we only obtained IgG antibodies, which are the default subclass for CSR in mouse B cells. We speculate that it may be possible to obtain other classes and subclasses of antibodies by addition of specific cytokines to the hybridoma cells during CSR, as has been observed for cultured mouse B cells. It is important to screen class-switched antibodies for retention of antigen-binding activity because SHM also occurs during CSR. We believe that class switching of low affinity IgM to IgG by itself is of limited utility because the resulting IgG is likely to display low functional avidity due to the loss of eight binding sites. Rather, performing simultaneous CSR and selection of high affinity antibodies by our approach may be particularly useful to both affinity mature and class switch low affinity IgM antibodies to high affinity IgG antibodies.

Mimicking the germinal center reaction in hybridoma cells possesses several attractive features. SHM and CSR can be conveniently initiated by lentiviral transduction of hybridoma cells and then stopped after desirable antibodies are identified by removing doxycycline for the Tet-on system or by Cre-mediated excision of the LoxP-flanked AID cassette. Membrane-bound antibodies on the surface of viable hybridoma cells can be used for rapid identification of desirable hybridoma cells whereas secreted antibodies can be collected from the culture medium for further analysis of antibody properties. Controllable expression of AID in myeloma fusion partners may extend this technology to the generation of new hybridoma cells with the built-in capability to perform “on demand” SHM and CSR. We anticipate that this technology may be particularly useful for generating high affinity IgG antibodies against “difficult” antigens such as carbohydrates, haptens, polymers, lipids, and highly homologous proteins and peptides that often produce low affinity IgM responses. Although our study was performed in mouse hybridoma cells, it may be feasible to extend this technology to perform SHM and CSR in human...
hybridoma cells, for example in those generated from transgenic antibody mice, from immunized or infected human patients or from human immune mice.47-50

Methods

Cell lines and reagents
FO myeloma cells (PTA-11450),51 BALB/3T3 mouse fibroblasts (CCL-163), CC49 (IgG1 mAb against TAG-72, HB-9459), L6 (IgG1, mAb against human L6 antigen, HB-8677), BC3 (IgG1 mAb against human CD3 epsilon chain, HB-10166), and PEG-16 (IgG3 mAb against influenza virus, CCL-189) hybridoma cells were purchased from American Type Culture Collection. Hybridoma cell lines AGP4 (IgM mAb against polyethylene glycol), 3.3 and 6–3 (IgG1 mAbs against polyethylene glycol), 7G8 (IgG, mAb against human β-glucuronidase), and 3D8 (IgM mAb against B16F10 melanoma) were developed in our lab and have been described.24,52,53 Human 293FT cells were kindly provided by Dr. Ming-Zong Lai (Institute of Molecular Biology, Academia Sinica, Taiwan). All cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 2.98 g/L HEPES, 2 g/L NaHCO3, 10% fetal calf serum (HyClone), 100 U/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO2 in air. Methoxy-PEG750-NH2, methoxy-PEG1K-NH2, methoxy-PEG2K-NH2, methoxy-PEG3K-NH2, hydroxy-PEG5K-NH2, methoxy-PEG10K-NH2, methoxy-PEG20K-NH2 (750, 1,000, 2,000, 3,000, 5000, 10,000, and 20,000 Da, respectively), 4-arm poly(ethylene oxide)10K-NH2, 2-aminomethyl-18-crown-6 and 18-crown-6 were purchased from Sigma-Aldrich.

DNA plasmid construction
The plasmids pAS4w.1.Ppuro (Fig. S3), which contains a tetracycline-response element promoter (TRE) for doxycycline-inducible gene expression (Tet-on system), pLKO_AS3w.Ppuro (Fig. S4) and pLKO_AS3w.Pneo (Fig. S5), which contain a CMV early enhancer/chicken β actin (CAG) promoter for cDNA gene expression, and pLKO_AS3w.Ppuro-eGFP (Fig. S6), which contains an eGFP gene, are lentiviral vectors. These plasmids along with pCMVΔR8.91 packaging plasmid54 and pMD.G VSV-G envelope plasmid55 were obtained from the National RNAi Core Facility (Institute of Molecular Biology, Genomic Research Center, Academia Sinica). To generate a stoppable murine AID (AID) expression system, we designed a loxP flanked loxP-CMV-AID-HA-F2A-eGFP-loxP expression cassette (pCMV-AID-loxP). A HA-tagged murine activation-induced deaminase (AID-HA) DNA fragment was cloned from splenocytes isolated from BALB/c mice by RT-PCR. To monitor the expression of AID-HA, a furin-2A (F2A)56 based bicistronic expression strategy was used to link an enhanced green fluorescence protein (eGFP gene) downstream of the AID-HA gene. A HA-F2A-eGFP fragment containing part of the HA tag and eGFP gene was amplified from pLNCX-anti-PEG-eB7.57 The CMV promoter was also cloned by PCR from pLNCX-anti-PEG-eB7. The eGFP fragment was cloned by PCR from pLKO_AS3w.Ppuro-eGFP. The CMV-AID-HA-F2A-eGFP cassette was then created by assembly PCR from CMV, AID-HA and F2A-eGFP fragments and inserted into the pLKO_AS3w.Ppuro plasmid in which the CAG promoter was replaced with the CMV promoter. To introduce loxP sites, annealed oligonucleotides were inserted into a Spe I site upstream of the CMV promoter and in a Pme I site downstream of eGFP, respectively. The resultant plasmid, pCMVΔR8.91 into 293FT cells to produce recombinant lentivirus, which was used to infect hybridoma cells to introduce the AID gene into the genome.

We also constructed an inducible AID expression vector. rtTA-M2 was amplified from pRetroX-Tet-On Advanced (Clontech Laboratories, Inc.) by PCR and then mutated using multisitedirected mutagenesis58 to obtain the rtTA-V14 gene, which only

![Figure 8. Mild affinity purification of PEGylated compounds. (A) Schematic outline of temperature-dependent affinity purification of PEG-Qdot655. (B) Oxidized 3.3 or 2B5 antibodies were immobilized on UltraLink® Hydrazide Resin and packed into columns. PEG-Qdot655 were passed into the columns and then the columns were washed with cold PBS (4°C) and eluted with 37°C PBS or citrate buffer (pH = 3.0). The fluorescence of PEG-Qdot655 was detected on an IVIS 200 optical imaging system (Xenogen).](image-url)
requires 10 ng/mL of doxycycline to achieve similar gene induction levels as the wild type rtTA at 1000 ng/mL of doxycycline in the Tet-on system. An IRES-rtTA-V14 fragment was generated by assembly PCR. A Nhe I- Pme I digested AID-HA-F2A-eGFP fragment and the IRES-rtTA-V14 fragment were inserted into pAS4w.1.Ppuro to create pAS4w.1.Ppuro-AID-F2A-eGFP-IRES-rtTA-V14, denoted as pTetOn-AID.

A DNA fragment encoding the DsRed2 gene was amplified from pDsRed2 (Clontech Laboratories, Inc.) and inserted into pLKO_AS3w.Pneo to generate pAS3w.Pneo-DsRed2. An amber stop codon was introduced into pAS3w.Pneo-DsRed2 at nucleotide position 51918 by site directed mutagenesis using a QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) to generate pDsRed2s.

Biotinylation of PEG and β-glucuronidase
4arm-PEG10K-NH2, methoxy-PEG5K-NH2 and methoxy-PEG2K-NH2 (Laysan Bio) dissolved in DMSO at 2 mg/mL were mixed with a 6-fold (for 4arm-PEG10K-NH2) or 2-fold (for methoxy-PEG5K-NH2 and methoxy-PEG2K-NH2) molar excess of EZ-link NHS-LC-Biotin (Pierce) or Alexa Fluor® 647 succinimidyl esters (Invitrogen) in DMSO for 2 h at room temperature to produce biotinylated 4arm-PEG10K or Alexa Fluor 647 conjugated methoxy-PEG5K and methoxy-PEG2K, respectively. These compounds were diluted in a 5-fold volume of ddH2O and dialyzed (molecular weight cut-off ~12,000–14,000 daltons) against ddH2O to remove free EZ-link NHS-LC-biotin, sterile filtered and stored at -80°C.

Analysis of membrane-bound immunoglobulin on hybridoma cells
Surface expression of mouse immunoglobulin on live hybridoma cells was measured by staining cells with 2 μg/mL of goat anti-mouse Ig (ICN Pharmaceuticals) or goat anti-E. coli antibody (Abcam) as a negative control in PBS containing 0.05% BSA at 4°C for 1 h. The cells were washed three times with cold PBS and stained with 2 μg/mL FITC-conjugated rabbit anti-(goat IgG F(ab)′2) antibody (ICN Pharmaceuticals). The 3.3 and 7G8 hybridoma cells were also stained with biotinylated 4arm-PEG10K (0.5 nM) or biotinylated β-glucuronidase (5 μg/mL) in Hank’s balanced salt solution (HBSS), 2% FBS for 30 min at 4°C followed by Alexa Fluor 647-conjugated streptavidin (2 μg/mL) and analyzed by a FAC.
mL) (Jackson ImmunoResearch Laboratories) for 30 min at 4°C. Unbound probes were removed by washing with cold PBS twice. The surface fluorescence of $10^6$ viable cells was measured on a BD™ LSR II flow cytometer (Becton Dickinson) and analyzed with Flowjo (Tree Star).

**Lentiviral transduction of the AID gene into hybridoma cells**

Recombinant lentiviral particles were packaged by co-transfection of 7.5 µg pCMV-AID-loxP or pTetOn-AID with 6.75 µg pCMVΔR8.91 packaging plasmid and 0.75 µg pMD.G VSV-G envelope plasmid using 45 µL TransIT-LT1 transfection reagent (Mirus Bio) in 293FT cells grown in a 10 cm culture dish (90% confluency). After 48 h, lentiviral particles were harvested and concentrated by ultracentrifugation at 50,000xg for 1.5 h at 4°C. Lentiviral particles were suspended in culture medium containing 5 µg/mL polybrene and filtered through a 0.45 µm filter. Hybridoma cells were seeded in 6-well plates (1 x 10⁵ cells/well) one day before viral infection. Lentivirus containing medium was added to the cells, which were then centrifuged for 1.5 h (500xg, 32°C). The cells were selected in complete medium containing puromycin (5 µg/mL) to measure membrane-bound immunoglobulin levels. Unbound probes were removed by washing with cold PBS twice. Cells displaying high Alexa Fluor 647 fluorescence (1% of total cells) were collected on a FACSAria cell sorter and cultured for 2 wk before the cells were sorted again. The PEG chain length and branching of the PEG probe was progressively decreased from 4arm-PEG-ΔloxP to linear PEG₃₅ and linear PEG₃₅ during subsequent rounds of sorting. After 5 rounds, single 3.3/AID cells were collected into 96-well plates and AID expression was stopped by transient transfection of pLM-CMV-mCherry-P2A-Cre into hybridoma clones.

**Antibody production and purification**

2.5 x 10⁷ of selected 3.3/loxP-AID variant hybridoma cells (1E3 and 2B5) in 15 mL culture medium (DME, 5% FBS) were inoculated into a CELLine CL 1000 two-compartment bioreactor (INTEGRA Biosciences AG). The antibody-containing culture medium was harvested every 7 d and then purified by protein A Sepharose 4 Fast Flow chromatography (GE Healthcare). Collected antibody was dialyzed against PBS and sterile filtered. Antibody concentrations were determined by the bicinchoninic acid (BCA) protein assay (Thermo Scientific).

**Site directed mutagenesis of antibody 2B5**

The recombinant 2B5 antibody gene was cloned from 2B5 hybridoma cDNA by RT-PCR. The 2B5 light chain and heavy chain DNA were joined by a composite furin-2A bicistronic expression peptide linker in pLNCX-anti-PEG-eB7. An EcoR I- Pme I digested 2B5 IgG fragment was inserted into pAS3w. Ppuro to create pAS3w.Ppuro-2B5. Site-directed mutagenesis of Vᵢ/V₂₃A and V₄/K₅₃N was performed in a 50 µL mixture containing 20 ng of pAS3w.Ppuro-2B5 template DNA plasmid, 15 pmole of each primer, 20 nmole of dNTPs, 2 U of Phusion high-fidelity DNA polymerase (Thermo Scientific) in 1 x Phusion buffer. Thermal cycling used an initial denaturation at 95°C for 0.5 min; 18 cycles at 95°C for 0.5 min, 55°C for 1 min and 68°C for 11 min. After cooling to 37°C, 2 U of Dpn I restriction enzyme (NEB) was directly added to the amplification reaction at 37°C for 1.5 h. Four microliters of the Dpn I digested sample was used to transform DH5α competent cells by the heat shock method. 3T3 cells that stably secreted 2B5/V₂₃A (2B5ΔV) and 2B5/K₅₃N (2B5ΔK) antibodies were generated by lentiviral transduction and selected in puromycin (10 µg/mL) as described above. The culture medium of cells producing 2B5ΔV and 2B5ΔK recombinant antibodies was harvested from CELLine adher 1000 bioreactors every 7–10 d and the antibodies were purified by protein A Sepharose 4 Fast Flow chromatography.
Antibody ELISA
Maxisorp 96-well microplates (Nalge-Nunc International, Roskilde, Denmark) were coated with 0.5 μg/well methoxy-PEG\textsubscript{750}-NH\textsubscript{2}, methoxy-PEG\textsubscript{20k}-NH\textsubscript{2}, methoxy-PEG\textsubscript{10k}-NH\textsubscript{2}, methoxy-PEG\textsubscript{3k}-NH\textsubscript{2}, hydroxy-PEG\textsubscript{5k}-NH\textsubscript{2}, methoxy-PEG\textsubscript{10k}-NH\textsubscript{2}, methoxy-PEG\textsubscript{20k}-NH\textsubscript{2} or 4-arm poly(ethylene oxide)\textsubscript{10k}-NH\textsubscript{2} in 50 μL/well 0.1 M NaHCO\textsubscript{3}/Na\textsubscript{2}CO\textsubscript{3} (adjusted to pH 8.0 with HCl) buffer for 3 h at 37°C and then blocked with 200 μL/well dilution buffer (5% skim milk in PBS) at 4°C overnight. Antibodies were pre-incubated at 37°C for up to 5 d to check thermal stability. Graded concentrations of antibodies in 50 μL 2% skim milk in PBS were added to the plates at 4°C, RT or 37°C for 1 h. The plates were washed with PBS three times at 4°C, RT or 37°C, respectively. HRP-conjugated donkey anti-mouse IgG Fc (2 μg/mL) in 50 μL dilution buffer were added for 1 h at 4°C, RT or 37°C for the plates. The plates were washed with PBS three times at 4°C and were then incubated with HRP-conjugated donkey anti-mouse IgG Fc (2 μg/mL) at 4°C for 1 h. For crown ether ELISA assays, maxisorp 96-well microplates were coated with 0.5 μg/well amino-PEG\textsubscript{2k}-NH\textsubscript{2} or human β-glucuronidase as described above. 3-fold serial dilutions of 18-crown-6 starting at 120 mM were prepared and mixed 1:1 (v/v) with 20 μg/mL of 3.3, 2B5 or 7G8 antibodies (thus the final concentration of the antibodies was 10 μg/mL). The mixture was added to the plates at 4°C for 1 h. The plates were washed with PBS three times at 4°C and were then incubated with HRP-conjugated donkey anti-mouse IgG Fc (2 μg/mL) at 4°C for 1 h. For crown ether ELISA assays, maxisorp 96-well microplates were coated with 0.5 μmole / well 2-aminomethyl-18-crown-6 as described above. Graded concentrations of antibodies (3.3, 2B5 or 7G8) in 50 μL 2% skim milk in PBS were added to the plates at 4°C, 25°C or 37°C for 4 h. The plates were washed with PBS two times at 4°C, 25°C or 37°C, respectively. Biotin-conjugated goat anti-mouse IgG Fc (2 μg/mL) (Jackson ImmunoResearch Laboratories) in 50 μL dilution buffer were added for 1 h at 4°C, 25°C or 37°C. The plates were washed as described above at different temperatures. Five micrograms of biotinylated peroxidase (Invitrogen) and 10 μg of streptavidin (Thermo Scientific) were pre-incubated in 15 mL PBS for 30 min at room temperature to allow complex formation before 50 μL was added to the wells. Unbound antibodies were washed with PBS four times at 4°C, 25°C or 37°C. In all cases, the bound peroxidase activity was measured by adding 150 μL/well ABTS solution [0.4 mg/mL, 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid), 0.003% H\textsubscript{2}O\textsubscript{2}, and 100 mM phosphate-citrate, pH 4.0] for 30 min at room temperature. The absorbance (405 nm) of wells was measured in a microplate reader (Molecular Device).

Fab fragmentation of IgG
Papain (Sigma-Aldrich) was dissolved to a final concentration of 0.1 mg/mL in PBS supplemented with 20 mM l-cysteine and 20 mM EDTA (Sigma-Aldrich) and the pH was then adjusted to 7.2. An equal volume of purified 3.3, 1E3 or 2B5 anti-PEG antibody (2 mg/mL) was added to the papain solution and incubated at 37°C for 2.5 h. One-tenth volume of 0.3 M iodoacetamide solution (Sigma-Aldrich) was added to stop the reaction. The 3.3, 1E3 and 2B5 anti-PEG Fab fragments were purified by affinity chromatography on a PEG affinity column, generated by swelling Ig of CNBr-activated Sepharose 4B (GE Healthcare) in 1 mM HCl (pH 3) for 30 min, washing with coupling buffer (0.1 M NaHCO\textsubscript{3}, pH 8.3) and adding five moles of methoxy-PEG\textsubscript{5k}-amine (Laysan Bio) per mL gel in coupling buffer for 4 h at 25°C. Remaining active groups on the CNBr-activated Sepharose were blocked by adding 1/10 volume of 1M Tris (pH 8) to the gel at 25°C for 2 h. The PEG coupled Sepharose was washed with 0.1 M acetate buffer (pH 4) containing 0.5 M NaCl followed by 0.1 M Tris (pH 8) containing 0.5 M NaCl. Papain digested antibodies were loaded to the PEG-resin column at 4°C for 45 min and washed with cold PBS to removed papain and Fc fragments. The PEG-resin bound anti-PEG Fab fragments were eluted with 100 mM glycine buffer (pH 3) and dialyzed against PBS.

PEGylation of hen egg white lysozyme
Three mg/mL hen egg white lysozyme (HEL) (Sigma-Aldrich) in PBS (pH 8.0) was mixed with a 4-fold molar excess of methoxy-PEG\textsubscript{2k}-sucinimidylpropionate (Shearwater Polymers) for 2 h at 25°C to produce mono-PEGylated HEL (PEG\textsubscript{2k}-HEL). One-tenth volume of 1 M glycine solution was added to stop the reaction. Unreacted PEG was removed by gel filtration on a Sephacryl S-300 HR column. The concentration of PEG\textsubscript{2k}-HEL was determined by the BCA assay (Thermo Scientific) with bovine serum albumin used as the reference protein.

Binding kinetic analysis of anti-PEG antibodies by surface plasmon resonance
The binding kinetics of 3.3, 1E3 and 2B5 anti-PEG Fab fragments was measured on a Biacore T-200 (GE Healthcare) at 4°C, 25°C and 37°C. PEG\textsubscript{2k}-HEL was immobilized on a CM5 chip (GE Healthcare) by using the standard procedure for amine coupling through the EDC/NHS reaction. A total immobilization of 57 resonance units (RUs) was achieved. Binding was determined at a constant flow rate of 65 μL/min of various concentrations of the antibodies in HEPES buffered saline.

Thermal stability of antibodies
Antibodies were dialyzed in PBS, degassed, and added into the sample chamber of a differential scanning calorimeter (Nano DSC III) (TA Instruments) at concentrations of 0.5 mg/mL. Degassed PBS was injected into the reference chamber. Differential power was monitored as each antibody-buffer pair was heated linearly from 10°C to 110°C at a rate of 1°C per minute under a fixed pressure of 3 atm. Buffer-buffer (degassed PBS) scans were also collected for baseline subtraction using the same procedure as for the antibody samples.

Binding of antibodies to crown ether by surface plasmon resonance
The binding activity of antibodies to 18-crown-6 compounds was measured on a Biacore T-200 (GE Healthcare) at defined temperatures. The 2-aminomethyl-18-crown-6 was immobilized on a CM5 chip by using the standard procedure for amine coupling through the EDC/NHS reaction. Injection of 2-aminoethyl-18-crown-6 (10 mM in 50 mM sodium borate buffer, pH 8.5) to a EDC/NHS activated CM5 chip was performed at a constant flow rate of 10 μL/min for 30 min. The remaining succinimide esters were inactivated by the injection of ethanolamine. A total immobilization of 279.4 resonance units (RUs)
was achieved. Antibody binding analysis was performed at a constant flow rate of 50 μL/min of the antibodies at 1 μM in HEPES buffered saline at 4°C, 25°C and 37°C.

Affinity purification of PE Gylated nanoparticles by anti-PEG antibodies

PEG-Qdot655 nanoparticles were purified by affinity chromatography on the anti-PEG antibody resin columns. Briefly, 5 mg of 3.3 or 2B5 anti-PEG antibodies in coupling buffer (0.1 M sodium acetate, 0.15 M sodium chloride, pH 5.5) was reacted with 10 mM sodium meta-periodate (Thermo Scientific Pierce) in the dark at room temperature for 30 min. Sodium meta-periodate was removed on a Zeba™ Spin desalting column and the oxidized antibodies were then incubated with 1 mL of UltraLink® Hydrazide Resin containing 0.1 M aniline (Thermo Scientific) at room temperature for 4 h. The anti-PEG resin was packed into a column and washed with PBS 3 times. Five hundred microliters of PEG-Qdot655 solution (32 nM in PBS) was loaded into the 3.3 or 2B5 anti-PEG columns at 4°C. The columns were washed with cold PBS and bound PEG-Qdot655 nanoparticles were eluted with 37°C PBS or 100 mM citrate buffer (pH 3). The particles were transferred into a Nunc F96 MicroWell black polystyrene plate (200 μL/well) and the fluorescence of PEG-Qdot655 (excitation/emission: 450 nm/660 nm) was detected on an IVIS 200 optical imaging system (Xenogen).

Immunoglobulin ELISA

Maxisorp 96-well microplates were coated with 0.5 μg/well goat anti-mouse IgG+IgA+IgM (Jackson ImmunoResearch Laboratories) in 50 μL/well 0.1 M NaHCO₃/Na₂CO₃ (adjusted to pH 8.0 with HCl) buffer for 3 h at 37°C and then blocked with 200 μL/well dilution buffer (5% skim milk in PBS) at 4°C overnight. Diluted hybridoma supernatants in 50 μL 2% mouse IgG, IgA, or IgM (MP Biomedicals, 2 μg/mL) with 200 μL/well ABTS solution for 30 min at room temperature for 4°C. The bound peroxidase activity was measured using a microplate reader. The isotypes of class-switched AGP4 and 3D8 antibodies were determined with a Mouse MonoAb-Id kit (Zymed Laboratories) according to the manufacturer’s instructions.

FACS analysis of class switched 3D8 antibody variants

B16F10 cells were stained for 30 min at 4°C with culture supernatant from 3D8 or 3D8/loxP-AID cells. The cells were washed three times with cold PBS and stained with 2 μg/mL PE-conjugated goat anti-mouse IgG Fc antibody (Jackson ImmunoResearchLaboratories). Unbound antibodies were removed by washing with cold PBS twice. The surface fluorescence of 10⁶ viable cells was measured on a BD™ LSR II flow cytometer and analyzed with Flowjo.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by Academia Sinica and a research grant from the National Science Council, Taipei, Taiwan (NSC 102–2320-B-001–013-MY3). The authors thank Dr. Shuchuan Jao of the Biophysics Core Facility, Scientific Instrument Center at Academia Sinica for assistance in performing Biacore T200 and Nano DSC III experiments. We also thank Ms. Chia-Chen Tai and Ms. Tzu-Wen Tai of the Flow Cytometry Core, Scientific Instrument Center at the Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan for help with the LSR II flow cytometer and FACSARia cell sorter. We appreciate helpful discussions with Dr. Mi-Hua Tao of the Institute of Biomedical Sciences and Dr. Andrew H.-J. Wang and Dr. Meng-Chiao Ho of the Institute of Biological Chemistry at Academia Sinica. We appreciate help with lentivirus production by the National RNAi Core Facility, Institute of Molecular Biology / Genomic Research Center, at Academia Sinica, Taipei, Taiwan.

Author Contributions

Y.-C.S. and S.R.R. conceived the project and designed the experiments and analyses. Y.-C.S., T.S.A.Q., H.-Y.T., and B.-M.C. performed experiments. K.-H.C. cloned recombinant antibody genes. Y.-C.S., T.-L.C., and S.R.R. analyzed data and wrote the manuscript.

Supplemental Materials

Supplemental materials may be found here: www.landesbioscience.com/journals/mabs/article/29124/

References

1. Söderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Abeg AM, Nilsson A, Jansson B, Ohlin M, Wingren C, et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000; 18:852-6; PMID:10932154; http://dx.doi.org/10.1073/nrb.60755
2. Hoet RM, Cohen EH, Kent RB, Rookey K, Altobell L 3rd, Zhang X, et al. Coupling mammalian antibody genes. Y.-C.S., T.-L.C., and S.R.R. analyzed data and wrote the manuscript.

4. Crameri A, Cwirla S, Stemmer WP. Construction and evolution of antibody- phage libraries by DNA shuffling. Nat Med 1996; 2:100-2; PMID:8564822; http://dx.doi.org/10.1038/nm919-100
5. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553-7; PMID:9181578; http://dx.doi.org/10.1038/ntbi0697-55
6. Bowers PM, Horlick RA, Neben TY, Toboian RM, Tomlinson GL, Dalton JL, Jones HA, Chen A, Altbell L 3rd, Zhang X, et al. Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci U S A 2011; 108:20455-60; PMID:2125898; http://dx.doi.org/10.1073/pnas.1114010108
7. Ramsden DA, van Gent DC, Gellett M. Specificity in V(D) recombination: new lessons from biochemistry and genetics. Curr Opin Immunol 1999; 9:114-20; PMID:9937986; http://dx.doi.org/10.1016/S0952-7915(97)80167-7
8. Couch EE, Li Z, Takizawa M, Fichtner-Feigl S, Gouziri P, Montäfo C, Feigenbaum L, Wilson P, Jans S, Papavassiliou FN, et al. Regulation of AID expression in the immune response. J Exp Med 2007; 204:1145-56; PMID:17525220; http://dx.doi.org/10.1084/jem.20061952
9. Odgaard VH, Scharz DG. Targeting of somatic hypermutation. Nat Rev Immunol 2006; 6:573-83; PMID:16868548; http://dx.doi.org/10.1038/nri1896
10. Jacob J, Przyplea J, Miller C, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-enopyrrolo)acetyl. III. The kinetics of V region mutation and selection in germinal center B cells. J Exp Med 1993; 178:1293-307; PMID:8376935; http://dx.doi.org/10.1084/jem.178.4.1293
11. Martin A, Bardwell PD, Woo CJ, Fan M, Shulman MJ, Scharff MD. Activation-induced cytidine deaminase: A potential target for therapy on somatic hypermutation in hybridomas. Nature 2002; 415:802-6; PMID:11823785; http://dx.doi.org/10.1038/nature01744

www.landesbioscience.com

mAbs

1081
52. Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM, Roffler SR. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther 2007; 14:187-200; PMID:16977328; http://dx.doi.org/10.1038/sj.cgt.7700999
53. Tsai NM, Chen BM, Wei SL, Wu CW, Roffler SR. Anti-tumor immunoglobulin M increases lung metastasis in an experimental model of malignant melanoma. Clin Exp Metastasis 2003; 20:103-9; PMID:12705631; http://dx.doi.org/10.1023/A:1022616223359
54. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15:871-5; PMID:9306402; http://dx.doi.org/10.1038/nbt0997-871
55. Kahl CA, Marsh J, Fyffe J, Sanders DA, Cornetta K. Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J Virol 2004; 78:1421-30; PMID:14722997; http://dx.doi.org/10.1128/JVI.78.3.1421-1430.2004
56. Fang J, Qian J-J, Yi S, Harding TC, Tu GH, VanRoey M, Jossi K. Stable antibody expression at therapeutiC levels using the 2A peptide. Nat Biotechnol 2005; 23:584-90; PMID:15834403; http://dx.doi.org/10.1038/nbt1087
57. Chuang KH, Wang HE, Cheng TC, Tsou SC, Tseng WL, Hung WC, Tai MH, Chang TK, Roffler SR, Cheng TL. Development of a universal anti-polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes. J Nucl Med 2010; 51:933-41; PMID:20484433; http://dx.doi.org/10.2967/jnumed.10.071977
58. Sawano A, Miyawaki A. Directed evolution of green fluorescent protein by a new versatile PCR strategy for site-directed and semi-random mutagenesis. Nucleic Acids Res 2000; 28:E78; PMID:10931937; http://dx.doi.org/10.1093/nar/28.16.e78
59. Wu CH, Balasubramanian WR, Ko YP, Hsu G, Chang SE, Prijovich ZM, Chen KC, Roffler SR. A simple method for the production of recombinant proteins from mammalian cells. Biotechnol Appl Biochem 2004; 40:167-72; PMID:14725509; http://dx.doi.org/10.1042/BA20030184
60. Papapetrou EP, Lee G, Malani N, Serry M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, et al. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 2011; 29:73-8; PMID:21151124; http://dx.doi.org/10.1038/nbt.1717
61. Kabat EA, Te Wu T, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Collingdale, PA Diane Publishing, 1992.